Canaccord analyst John Young raised the firm’s price target on Merit Medical (MMSI) to $112 from $108 and keeps a Buy rating on the shares. The firm noted their announced acquisition of BioLife and the company’s reaffirmation of its FY25 guidance, and updated it to reflect the anticipated impact from the merger.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target raised to $108 from $106 at Wells Fargo
- Merit Medical Acquires Biolife Delaware for $120 Million
- Merit Medical’s Strategic Acquisition of Biolife Delaware: A Long-Term Growth Catalyst
- Merit Medical adjusts FY25 EPS view to $3.28-$3.41 from $3.29-$3.42
- Merit Medical acquires Biolife Delaware